Other studies determined that FOXC1 is significantly involved in breast cancer (BRCA) (Sabapathi et al., 2019) and also colon adenocarcinoma (COAD) (Zhang et al., 2020), pancreatic adenocarcinoma (PAAD) (Subramani et al., 2018), and non–small-cell lung cancer (NSCLC) (Chen et al., 2016). Here, FOXC1 is linked to breast carcinoma.